Context: Liver transplantation (LT) is considered the ideal therapy for patients with hepatocellular carcinoma (HCC) having cirrhosis but the shortage of liver donors and the risk of dropout from the wait list due to tumor progression severely limit transplantation. A new prognostic score, the HCC-model for end-stage liver disease (HCC-MELD), was developed by combining a-fetoprotein (AFP), MELD, and tumor size, to improve risk stratification of dropout in patients with HCC. Objectives: In this study, we investigated the ability of the HCC-MELD score in predicting the posttransplant for patients fulfilling Milan criteria (MC). Design: Two hundred patients with stage II tumor were retrospectively reviewed from a total of 1290 transplants performed at our institution from October 1997 through April 2015. Cox regression analysis was performed to identify the prognostic factors impacting the posttransplant survival. Results: Overall survival at 1, 5, and 10 years was 89.3%, 71.1%, and 67.2%, whereas disease-free survival was 86.4%, 66.5%, and 52.4%, respectively. Multivariate analysis showed HCC-MELD score (hazard ratio [HR] 39.6, P < .001) and microvascular invasion (HR 2.41, P ¼ .002) to be independent risk factors for recurrence, whereas HCC diameter (HR 1.15, P ¼ .041), HCC-MELD (HR 15.611, P ¼ .006), and grading (HR 2.17, P ¼ .03) proved to be predictive factors of poor overall survival. Conclusion: Our study showed the validity of the HCC-MELD equation in the evaluation of patients undergoing LT for HCC. This score offers a reliable method to assess the risk of waiting list dropout and predict posttransplantation outcomes.
Introduction
The incidence of hepatocellular carcinoma (HCC) seems to be rising rapidly over the years because new cases are expected due to patients' long-term chronic viral hepatitis. Furthermore, it is estimated that nonalcoholic fatty liver disease related to obesity may lead to an increased incidence of HCC. [1] [2] [3] Among the therapeutic options available to deal with HCC, liver resection (LR) and local ablative procedures are regarded as potentially curative treatments, but their effect on the functional reserve of the liver restricts their application. Also, there is a high chance of recurrence in the liver remnant. [4] [5] [6] [7] Liver transplantation (LT) is the most effective treatment in early unresectable HCC with impaired liver function. In addition, transplantation offers the advantage of being a valid oncological therapy in the radical treatment of HCC as it removes the tumor and simultaneously replaces the cirrhotic liver. [8] [9] [10] The initial experiences of LT for HCC were disappointing. These poor results were related to an inadequate selection of patients for transplantation. In 1996, Mazzaferro et al demonstrated a 4-year survival of 85% and a posttransplant recurrence of 8% in a selected cohort of 48 patients through the use of restrictive selection criteria, subsequently called Milan criteria (MC; a solitary lesion <5 cm or multiple lesions no more than 3 in number, none of which are larger than 3 cm in the absence of macrovascular invasion and metastasis).
However, transplantation is severely limited by the scarcity of organs and the potential progression of the tumor while waiting for an organ. The international guidelines have limited transplantation in patients with HCC with an expected 5-year survival greater than 50% or with an expected survival at 5 years equal to that of transplants performed for benign disease. 12 The current United Network for Organ Sharing (UNOS) staging classification for HCC has incorporated the MC into stage I and stage II to ensure that all patients who receive an organ have a reasonable chance at long-term survival.
In 2002, the model for end-stage liver diseases (MELD) score system was chosen as a criterion for organ allocation in patients undergoing LT. This system is based on organ allocation for patients with increased risk of mortality on the waiting list. [13] [14] [15] However, the mortality endpoint system, sickest first policy, has been declared inadequate in assessing patients with HCC, as it is supposed that the risk of tumor progression is greater in these patients than the risk of dying on the waiting list due to complications related to cirrhosis. For this reason, policy makers have assigned a priority score for patients with HCC: MELD exception points of 24 for stage I and 29 for stage II. This balances the risk of tumor progression with the risk of death defined by MELD. Subsequently, new studies have highlighted an overestimation in the risk of HCC progression during the waiting list time, so the extra MELD points were only awarded for stage II and priorities for stage I were abolished. However, these corrections to the allocation policy, regarded as useful in maintaining equality in access to deceased donor liver transplant for HCC and non-HCC recipients, did not produce the desired effect. In fact, HCC liver transplant candidates still have an advantage over non-HCC patientsin accessing the liver donor pool. 16, 17 A calculated continuous priority score was therefore developed to improve the probability of dropout for candidates with HCC within 90 days of listing. The HCC-MELD equation incorporates MELD score, a-fetoprotein (AFP), and tumor size. This system was developed by Freeman et al 18 in 2006 and validated on a large number of patients waiting for transplantation. The ability of this score to assess survival posttransplant recently emerged. 19 The aim of this study is to evaluate the factors impacting survival posttransplant and to test the ability of the HCC-MELD score to predict survival posttransplant in a population of patients transplanted with HCC fulfilling MC pretransplantation.
Patients and Methods

Study Design and Population
A prospectively collected database of all the 1290 liver transplants performed in 1158 patients at our institution from October 1997 through April 2015 was retrospectively reviewed. This study was reviewed and approved by the institutional review board of Papa Giovanni XXIII Hospital. Recipients were divided almost equally, with 571 pediatric and 719 adults. Thus, on exclusion of the pediatric patients, over a 14-year period from 2001 to 2015, 224 adult patients with HCC were transplanted, and 15 patients with unconfirmed HCC and 6 patients with a final diagnosis of combined hepatocellular and cholangiocarcinoma on the hepatectomy specimen were excluded from the analysis. Three further patients were excluded, having died <30 days postoperatively. Therefore, the final study cohort included 200 patients with HCC undergoing LT.
The preoperative diagnosis of HCC was based on the criteria defined by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. The diagnosis of HCC was considered reliable when the tumor characteristics were concordant with 2 imaging techniques, while tumor biopsy was confined to doubtful cases.
Patients were considered for transplantation if the tumor was within the MC: (1) a single tumor nodule with <5 cm diameter, (2) 2 or 3 nodules with <3 cm diameter, and (3) 
Setting and Treatments
During the waiting list time, a multidisciplinary team had the task of deciding the most appropriate preoperative treatment for each individual patient based on tumor staging and functional status of the liver. Generally, locoregional treatment with radiofrequency ablation was proposed in cases of single tumors less than 3 cm, whereas hepatic resection was indicated in cases where the tumor was single or multiple but confined to a single segment in patients with preserved liver function. Patients with multifocal HCC and impaired liver function were directed instead to treatment with transarterial chemoembolization. No intervention of downstaging was proposed for patients who did not meet the MC. Thus, the treatment given during the time on the waiting list had the sole aim of bridging to transplant to reduce the possibility of tumor progression. Every patient on the waiting list was followed up clinically; this included an ultrasound scan and measurement of serum AFP level every 3 months and contrast-enhanced dynamic computed tomography and magnetic resonance imaging every 6 months.
The LT was performed with the classic technique without venovenous bypass; the piggyback technique was only occasionally used. All explanted livers were examined for total number of HCC nodules, diameter of the nodules, presence of microvascular invasion, lymph node invasion, satellites, and precursor nodules. Satellite nodules were considered as all the small foci of tumor close to main nodules, whereas dysplastic nodules were defined as precursors. The degree of differentiation was defined according to Edmondson criteria. 20 Immunosuppression was according to our standard protocol of dual therapy with tacrolimus and steroids, with or without a basiliximab induction. Occasionally, patients received different regimens, having been enrolled in specific clinical trials.
Data Analysis
The following parameters were evaluated: overall patient and disease-free survival at 1, 3, and 5 years and Cox multivariate analysis of overall and disease-free survival. Continuous variables in each group were compared with the independent sample T test. Categorical parameters were compared using Fisher exact test. Survival rates after transplantation were calculated according to the Kaplan-Meier method and compared using the log-rank test. Recipient and tumor variables were entered in a univariate analysis and multivariate analysis for 5-year overall and disease-free survival using the Cox proportional hazard regression model. All covariates with P < .1 in the univariate analysis were included in a multivariate Cox regression analysis by forward stepwise method. Results are expressed as means with standard deviation. The P value of .05 or less was considered statistically significant. All the data analyses were carried out using SPSS 20 for Windows (IBM SPSS Statistics, Armonk, New York).
Results
The baseline demographics and clinical characteristics of the HCC population are reported in Table 1 . The majority of the study population was male (85.5%; n ¼ 171) with a median age at transplant of 55.9 (6.7) years. The most frequent etiology associated with HCC was hepatitis B and C-related cirrhosis. The patients transplanted for HCC had a compromised functional status as documented by the MELD score 13.2 (6.4) and the Child-Pugh score (CP A 40.5% vs CP B/C 59.5%). The mean HCC-MELD score was 0.104 (0.13) that corresponds to a dropout probability rate of 11% at 3 months.
Preoperative treatment was performed in 174 patients (87%): 84 patients had radiofrequency ablation, 50 had transarterial chemoembolization, 2 had alcohol injection, 24 patients had combined transarterial chemoembolization and radiofrequency, and 14 patients had previously undergone hepatic resection, 6of these patients received the liver transplant as a rescue therapy for recurrence.
A total of 200 patients received 211 liver transplants. Retransplantation was necessary in 11 patients (5.5%). Posttransplantation hospital mortality was 2.5% (5 patients). Graft types included deceased donor whole organs in 190 patients (95%) and deceased donor split liver grafts in 10 patients (right lobe, IV-VIII segments). Table 2 shows the tumor characteristics of the study population. The mean number of HCC nodules was 1.74 (1.1) and diameter was 2.94 (1.52) cm, and in 51% (n ¼ 102), the tumor was unifocal. In 58 patients (29%), histology of the explanted specimen showed that the HCC did not actually fulfill the MC due to an underestimation by the preoperative imaging. The patients were followed up for a median of 4.9 years (range: 6 month-14 years). Overall survival at 1, 5, and 10 years was 89.3%, 71.1%, and 67.2%, whereas disease-free survival was 86.4%, 66.5%, and 52.4%, respectively (Figure 1 ). Disease recurrence developed in 21 patients (10.5%) during followup. Median time from transplantation to HCC recurrence was 40.6 months (range 5.3-43.8 months). The tumor recurrence in the majority of the cases presented as extrahepatic metastases, principally of the lung and bone.
Multivariate Cox regression analyses on overall and diseasefree survival after transplant are represented in Table 3 (the univariate analyses are available as supplementary material online). The multivariate analysis shows that both HCC-MELD score and microvascular invasion are independent predictors of disease-free survival, whereas HCC-MELD score, degree of differentiation (grading), and HCC diameter (the largest nodule) are independently associated with an increased risk of death after transplantation.
A further survival analysis was conducted by stratifying the study population for a cutoff of 0.18 HCC-MELD score to identify a subgroup with poor prognosis. In fact, patients with HCC-MELD score >0.18 have an estimated survival rate of 51% at 5 years, worse than the group with <0.18 who have a survival of 70%. Kaplan-Meier survival curves in relationship to HCC-MELD cutoff are shown in Figure 2 .
Discussion
The introduction of strict selection criteria has permitted long-term survival posttransplant for patients with HCC, up to 85% at 5 years, and LT has increasingly been used to treat HCC in patients with end-stage disease. 21 Consequently, the price of such a brilliant result has been paid with an increase in the waiting time on the list. Currently, due to the shortage of organs, managing the waiting list so that patients do not die of tumor progression or complication due to cirrhosis remains an open and difficult problem to resolve. 7, 22 For this reason, finding an allocation system that can quantify the risk of dropout for patients on the waiting list is a complex challenge for policy makers. The MELD score has tried to respond to this need by defining the need for transplantation as risk of death on the waiting list within 90 days. The application of MELD with HCC exception was successful in achieving increased post-transplant survival in patients with HCC. However, in the MELD era, the number of patients with cancer transplanted in the United States has increased 3-fold, to such an extent that more than 25% of liver donors are allocated to patients with HCC. 16, 17, 23, 24 Thus, a more reliable and fair instrument, which considers variables that predict the natural progression of the tumor, has been developed in order to more accurately stratify the risk of dropout of patients on the waiting list for HCC. The HCC-MELD score consists of 3 variables: AFP, tumor size, and MELD score. These parameters are frequently associated with aggressive tumor behavior and adverse clinical outcomes. It was recently demonstrated that the HCC-MELD equation can evaluate posttransplant survival, including the probability of dropout in patients on the waiting list. Our study conducted on a selected cohort of pretransplant MC patients has confirmed that the HCC-MELD score is a model that can predict post liver transplant survival. In particular, our analysis shows that this model is also able to predict the disease-free survival after LT. The strength of this model should be particularly emphasized considering that, in the multivariate analysis, we included the HCC-MELD equation as a variable competitive with other histological variables that have always been recognized as strong prognostic factors of recurrence. Our data identify 0.18 as a threshold value of the HCC-MELD score, which corresponds to a probability of 18% dropout at 3 months, dividing the population into high and low risk of survival after transplantation. This value appears higher with respect to a recently published study by Cucchetti et al, 25 where an HCC-MELD score of 0.09 corresponding to 9.3% dropout was able to stratify the study population.
The main factors that determine HCC recurrence after liver transplant are related to the tumor burden and its underlying biology, as represented by number and size of tumor nodules, presence of vascular invasion, degree of differentiation, and level of serum AFP. [26] [27] [28] Our study confirms that HCC diameter, degree of differentiation, and microvascular invasion are independent prognostic factors of outcome after transplantation, whereas the number of HCC nodules is not.
In our cohort, 30% of patients were preoperatively understaged with respect to their posttransplant staging. In the majority of these patients, although the tumor was considered outside MC due to multifocal tumor foci, the long-term survival was not compromised.
The time interval between diagnosis of HCC and the subsequent transplantation is considered an important prognostic factor, as the dropout rate from the waiting list as a result of tumor progression increases according to time. Despite the extra MELD point, the risk of dropout for tumor progression remains a serious problem, especially for patients on the waiting list for a longtime. Bridging treatments with neoadjuvant intent are used in patients with HCC awaiting transplantation, with the aim of reducing the risk of neoplastic progression but also reducing posttransplant tumor recurrence and thus improve survival.
Bridging therapies are estimated to reduce the dropout risks for patients with HCC meeting MC from 0% to 10%. [29] [30] [31] Most of our patients received a bridging treatment before transplantation; however, no patient was a candidate for radioembolization. Radioembolization involves the transarterial infusion of microspheres containing Y90-loaded microspheres into the hepatic artery by transarterial techniques. It has recently emerged that this innovative method is capable of inducing a more rapid tumor response and lengthening the time of tumor progression compared to treatment with transarterial chemoembolization, suggesting a potential advantage as a bridging therapy in patients waiting for transplantation. 32, 33 Although the bridging treatment changed the tumor biology and reduced the risk of tumor progression in our patients, it did not have any effect on survival or tumor recurrence. In addition, the waiting time on the list did not have any effect on the outcome of the transplants, due to it being quite short, on average of 5 months.
The link between immunosuppression and oncogenesis is well established as the integrity of the immune system is one defense against cancer. Mammelian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) are used for the prevention of rejection in recipients of solid organs, but also have an antineoplastic effect, mainly antiproliferative and antiangiogenic. 34, 35 A number of studies have shown that mTOR inhibitors suppress cell proliferation and tumor growth in animal models of HCC. 36 In terms of a preventive effect after LT for HCC, recent data have shown that HCC recurrence rates may be improved with an mTOR immunosuppressant regimen. 37 In our study, no patients received preventive therapy with an immunosuppressive mTOR agent, while a switch to mTOR drugs was performed in the case of HCC recurrence posttransplant. It was therefore not possible to determine the impact of immunosuppressive therapy on posttransplant disease recurrence.
Although our study examined a homogeneous cohort of patients with long follow-up, the lack of a control group and the retrospective design were our limitations. In addition, it seems important to emphasize that it will be necessary to verify, in an independent and wider patient cohort, the ability of the HCC-MELD model to identify a subgroup of patients with worse prognosis even if classified within the MC.
Conclusion
We believe that the strength of this model is related to the combined effect of the preoperative variables, which are surrogates of the biological behavior of the tumor, and capable of making this continuous score very accurate and powerful in assessing the risk of waiting list dropout and predicting survival posttransplantation. Our study demonstrates the validity of the HCC-MELD equation in the evaluation of patients undergoing LT for HCC and in predicting the outcome posttransplantation.
